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Flecainide is a commonly used drug for rhythm control in
atrial ﬁbrillation (AF) with a good safety proﬁle1,2 when used
in the absence of structural heart disease. Flecainide has been
associated with acute hepatitis and cholestasis.3–6 Owing to
the small number of reported cases, however, the nature of
this purported association and potential predisposing factors
have not been clearly established. However, in view of the
growing number of individuals with AF in the North
American population (2–4 million),7 who may require
long-term medical treatment or treatment prior to ablation
therapy,2 it is important to identify predisposing conditions
for adverse liver reactions associated with ﬂecainide.
We therefore report the case of a 72-year-old man of
Northern European ancestry with α1-antitrypsin deﬁciency.
This condition is rare, with 1 in 2500 individuals carrying the
gene in those of the Northern and Western European
ancestry. It is a genetic disorder that results in production
of an abnormal antitrypsin that lacks antitrypsin activity that
would normally protect the lungs from neutrophil elastase.
The abnormal α1-antitrypsin accumulates in liver cells andKEYWORDS Atrial ﬁbrillation; Flecainide; Cardiovascular disease; Liver
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(http://creativecommons.org/licenses/by-nc-nd/4.0/).may lead to cirrhosis. Lungs and liver are therefore rendered
more susceptible to damage by toxins, especially lung
damage in smokers, resulting in emphysema and chronic
obstructive pulmonary disease.8 Our patient developed a
clinically signiﬁcant rise in liver enzymes and abdominal
discomfort in response to ﬂecainide prescribed for rhythm
control to abort increasingly frequent paroxysmal attacks of AF.Case report
The patient (DJAJ) was a 72-year-old white man with a
6-year history of recurrent episodes of paroxysmal AF that
occurred at monthly intervals and had been documented by
24-hour Holter monitor with symptom–arrhythmia correla-
tion. He had no history or symptoms of coronary arterial
disease or hypertension, although he had an apoE 4
genotype9 with a raised serum cholesterol, for which he
had been prescribed lovastatin (20 mg) several years
previously. The patient discontinued the statin after a few
days owing to right upper quadrant “heaviness.” No trans-
aminase levels were measured. Statin therapy was not
restarted. More recently the patient had carotid and large
coronary vessel magnetic resonance imaging. No evidence
of atheroma or arteriosclerosis was detected. He also had
Gilbert syndrome. The patient was a vegan, was a non-
smoker, consumedo1 drink of alcohol/week, and had taken
regular vigorous exercise throughout his life. Recently AF
had become symptomatic and was impairing his quality
of life.pen access article under the CC BY-NC-ND license
http://dx.doi.org/10.1016/j.hrcr.2016.01.005
KEY TEACHING POINTS
 Flecainide is a ﬁrst-line drug for rhythm control
with a long history of clinical use and, when given
in conjunction with a β-blocker, is associated with
remarkably few side effects.
 α1-Antitrypsin is produced in the liver and protects
pulmonary tissue from neutrophil elastase.
Genetically determined α1-antitrypsin deﬁciency in
its severe form results in lung damage, emphysema,
and chronic obstructive pulmonary disease and the
accumulation of misfolded α1-antitrypsin protein
in the liver, which is associated with development
of cirrhosis.
 This study of a patient with α1-antitrypsin
deﬁciency who, on repeated ﬂecainide challenge
for control of atrial ﬁbrillation, showed marked
rises in serum transaminases with right upper
quadrant pain indicates that α1-antitrypsin
deﬁciency may increase susceptibility to the
adverse hepatic effects of ﬂecainide.
 Patients with right upper quandrant pain on
ﬂecainide should have the drug stopped and
trasaminases and α1-antitrypsin measured.
 If α1-antitrypsin deﬁciency exists, then drugs
without hepatic metabolism should be preferred;
and if drugs with hepatic metabolism are used they
should be closely monitored.
 It is also possible that Gilbert syndrome may have
contributed to the hepatic effects seen with
ﬂecainide.
Heart Rhythm Case Reports, Vol 2, No 3, May 2016238Because of this increasing frequency of symptomatic AF,
the patient consulted his cardiologist. His cardiac function
overall was assessed as normal for his age following trans-
thoracic echocardiography that also demonstrated a trace of
regurgitation at mitral, tricuspid, and pulmonic valves; left
ventricular proximal septal thickening; and discrete nodular
thickening of the noncoronary cusp of a trileaﬂet aortic
valve. He was prescribed metoprolol 25 mg twice a day and
ﬂecainide 50 mg twice a day. During the next 5 days, he
experienced only 1 8-hour episode of AF on day 2 of
ﬂecainide and was able to swim, walk briskly, and climb
stairs, as previously. However, on day 2 of ﬂecainide he
became conscious of right upper quadrant (RUQ) discom-
fort, which was brought on by walking. By the fourth day,
walking resulted in considerable RUQ pain with each step
and there was also discomfort over the same area, even when
swimming. Flecainide was discontinued on the ﬁfth day. At
this time ultrasound detected no liver abnormality apart from
a number of hemangiomas that had previously been docu-
mented. At the end of 5 days of ﬂecainide administration,both transaminases (alanine transaminase and aspartate
transaminase) and alkaline phosphatase levels were elevated,
similar to other reports of adverse liver reactions associated
with ﬂecainide (Figure 1A, B).3–6 A comprehensive liver
evaluation was undertaken at this point, which ruled out
underlying infectious (hepatitis A, B, and C), autoimmune,
or metabolic (hemochromatosis, Wilson disease) liver dis-
ease. However, α1-antitrypsin deﬁciency was identiﬁed
(mean = 0.77 g/L; range, 0.63–0.85 g/L on multiple
measurements, lower-normal limit 0.89 g/L). During this
period, synthetic liver function (prothrombin time, bilirubin,
and albumin) remained normal. On discontinuation of
ﬂecainide, the fall in transaminases was rapid, and within 3
days of discontinuation of ﬂecainide all discomfort abated.
After 1 day, AF returned with increasing frequency and with
some episodes lasting 12–36 hours (Figure 1C). A lower
dose of ﬂecainide (12.5–100 mg/d; average 52.5 mg/d) was
reintroduced for 2 weeks (Figure 1D). However, because of
recurrent RUQ pain on walking, ﬂecainide was again
discontinued after 14 days. The RUQ pain during the low-
dose ﬂecainide administration was less severe and sporadic
than the predictable exercise-induced severe pain experi-
enced after higher-dose ﬂecainide administration. The
rechallenge with lower-dose ﬂecainide also resulted in
signiﬁcantly less of a transaminase rise (Figure 1A, B), and
bilirubin levels ﬂuctuated throughout but showed no obvious
relation to ﬂecainide administration. Flecainide was subsequently
discontinued and a trial of disopyramide 200 mg/d was under-
taken (Figure 1D). Although there was some apparent reduction
in length of daily AF episodes (Figure 1C), it was discontinued
owing to urinary symptoms consisting of hesitancy and poor
stream. Prostate-speciﬁc antigen rose from a baseline of 1.6 ng/L
to 2.0 ng/L and back to baseline 5 days after disopyramide
withdrawal. There was no change in liver enzymes during
disopyramide administration.
Conclusion
The current case adds to the growing body of reports that
ﬂecainide may cause abnormal liver enzymes. However,
adverse liver reactions associated with ﬂecainide remain rare,
with only a few reported cases in the literature.3–6 As a result,
liver enzymes are not routinely monitored; and severe RUQ
discomfort was required to trigger investigation of liver
enzymes in our case.
In our case, the patient had α1-antitrypsin deﬁciency, a
rare condition for which 1 in 2500 individuals carry the gene
among those of Northern and Western European ancestry,8
which might have contributed to the observed elevated liver
enzymes. Flecainide-mediated hepatocellular changes may
induce cytokine release and stimulate the synthesis of
α1-antitrypsin, an acute-phase protein.8 However, in patients
with α1-antitrypsin deﬁciency, the protective effect of
α1-antitrypsin may be reversed and enhance hepatocellular
damage, since a misfolded and therefore potentially toxic
serpin α1-antitrypsin is produced. The major clearance route
of ﬂecainide is via the hepatic cytochrome p450 system
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Heart Rhythm Case Reports, Vol 2, No 3, May 2016240We conclude that when ﬂecainide treatment is initiated,
RUQ discomfort, as in our patient, should trigger discontin-
uation of the drug and measurement of serum α1-antitrypsin
levels in addition to serum transaminases.
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